BRPI0413791A - composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos - Google Patents
composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostosInfo
- Publication number
- BRPI0413791A BRPI0413791A BRPI0413791-4A BRPI0413791A BRPI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A BR PI0413791 A BRPI0413791 A BR PI0413791A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- alkylaryl
- compound
- cor
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Soft Magnetic Materials (AREA)
- Lubricants (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
"COMPOSTO, MéTODO PARA O TRATAMENTO DE UM INDIVìDUO HUMANO OU ANIMAL QUE SOFRE DE, OU QUE é SUSCETìVEL A UM DISTúRBIO AUTO-IMUNE OU UMA CONDIçãO INFLAMATóRIA, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA A PREPARAçãO DE COMPOSTOS". Descreve-se compostos de fórmula (I): sendo que: A representa uma ligação, C~ 1-6~alquila ou CH=CHC~ 1-4~alquila; B representa ligação, O, S, SO, SO~ 2~, CO, CR¬ 7¬R¬ 8¬, CO¬ 2¬R¬ 14¬, CONR¬ 14¬R¬ 15¬, N(COR¬ 14¬)(COR¬ 15¬), N(SO¬ 2¬R¬ 14¬)(COR¬ 15¬) ou NR¬ 14¬R¬ 15¬; D representa ligação, ou C~ 1-6~ alquila; E representa arila substituído ou heteroarila substituído ou não substituído; Q representa um anel heteroarila ou arila com 5 ou 6 membros opcionalmente substituído; X representa O, S, SO, SO~ 2~, CO, CNRS, CNOR¬ 5¬, CNNR¬ 5¬R¬ 6¬, NR¬ 11¬ ou CR¬ 7¬R¬ 8¬; Y representa CR¬ 5¬OR¬ 11¬, CR¬ 5¬SR¬ 11¬, NOR¬ 5¬, CR¬ 5¬NR¬ 6¬R¬ 11¬, SO, SO~ 2~, CO, CNR¬ 5¬, CNOR¬ 5¬ ou CS; R¬ 1¬ e R¬ 1¬<39>, sendo que cada um representa independentemente H, C~ 1-6~alquila ou C~ 1-4~alquilarila; R¬ 2¬; representa CO~ 2~R¬ 12¬, CH~ 2~OR¬ 12¬ ou CONR¬ 12¬R¬ 13¬, CONR¬ 12¬OR¬ 13¬, NR¬ 12¬COR¬ 13¬, SR¬ 12¬, PO(OH)~ 2~, PONHR¬ 12¬ ou SONHR¬ 12¬; R¬ 3¬ representa H, C~ 1-6~alquila ou C~ 1-4~alquilarila; R¬ 4¬ representa heteroarila ou arila opcionalmente substituído; Z representa uma ligação. CH~ 2~, O, S, SO, SO~ 2~, NR¬ 5¬, OCR¬ 5¬R¬ 6¬, CR¬ 9¬R¬ 10¬O ou Z, R¬ 4¬ e Q em conjunto, formam um grupo tricíclico fundido opcionalmente substituído; R¬ 5¬ e R¬ 6¬ representam, cada um, independentemente, H, C~ 1-6~ alquila ou C~ 1-4~ alquilarila; R¬ 7¬ e R¬ 8¬, sendo que cada um representa independentemente H, halo, C~ 1-6~ alquila ou C~ 1-4~ alquilarila; R¬ 9¬ e R¬ 10¬ representam, cada um, independentemente, H, C~ 1-6~ alquila opcionalmente substituído por halo, ciano, OR¬ 11¬ ou NR¬ 6¬R¬ 11¬, C~ 1-4~ alquilarila opcionalmente substituído por halo, ciano, OR¬ 11¬ ou NR¬ 6¬R¬ 11¬, OR¬ 11¬ ou, em conjunto com o N a que estão ligados, R¬ 9¬ e R¬ 10¬ formam um grupo heterocíclico: R¬ 11¬ representa H, C~ 1-6~ alquila, C~ 1-4~ alquilarila ou COR¬ 5¬; R¬ 12¬ e R¬ 13¬, cada um, independentemente, representam H, C~ 1-3~ alquila, C~ 1-3~ alquilarila ou C~ 1-3~ alquil-heteroarila ou, em conjunto com a funcionalidade a que estão ligados, R¬ 12¬ e R¬ 13¬ formam um grupo heterocíclico: R¬ 14¬ e R¬ 15¬, cada um, independentemente, representa H, C~ 1-6~ alquila, C~ 1-4~ alquilarila ou C~ 1-4~ alquil-heteroarila ou, em conjunto com a funcionalidade a que estão ligados, R¬ 14¬ e R¬ 15¬ formam um heterocíclico ou grupo heterocíclico fundido: e derivados fisiologicamente funcionais dos mesmos, processos para sua preparação, formulações farmacêuticas contendo os mesmos, e seu uso como inibidores de enzimas de metaloproteinase de matriz (MMPs).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
PCT/EP2004/010319 WO2005026120A1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413791A true BRPI0413791A (pt) | 2006-11-07 |
Family
ID=29227079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413791-4A BRPI0413791A (pt) | 2003-09-13 | 2004-09-10 | composto, método para o tratamento de um indivìduo humano ou animal que sofre de, ou que é suscetìvel a um distúrbio auto-imune ou uma condição inflamatória, uso de um composto, composição farmacêutica, e, processo para a prearação de compostos |
Country Status (29)
Country | Link |
---|---|
US (3) | US7601729B2 (pt) |
EP (3) | EP2295408A1 (pt) |
JP (3) | JP2007505081A (pt) |
KR (3) | KR20120007566A (pt) |
CN (1) | CN1849306B (pt) |
AT (2) | ATE502922T1 (pt) |
AU (1) | AU2004272280C1 (pt) |
BR (1) | BRPI0413791A (pt) |
CA (1) | CA2538315C (pt) |
CY (1) | CY1109400T1 (pt) |
DE (2) | DE602004031991D1 (pt) |
DK (1) | DK1663970T3 (pt) |
ES (2) | ES2362954T3 (pt) |
GB (1) | GB0321538D0 (pt) |
HK (1) | HK1092141A1 (pt) |
HR (1) | HRP20080668T3 (pt) |
IL (1) | IL173305A (pt) |
IS (2) | IS2622B (pt) |
MA (1) | MA28039A1 (pt) |
MX (1) | MXPA06002458A (pt) |
NO (1) | NO20060540L (pt) |
NZ (2) | NZ573479A (pt) |
PL (1) | PL1663970T3 (pt) |
PT (1) | PT1663970E (pt) |
RU (2) | RU2370488C2 (pt) |
SG (1) | SG145685A1 (pt) |
SI (1) | SI1663970T1 (pt) |
WO (1) | WO2005026120A1 (pt) |
ZA (1) | ZA200602070B (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1856063B1 (en) * | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
ES2397284T3 (es) | 2006-08-22 | 2013-03-06 | Ranbaxy Laboratories Limited | Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos |
AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
MX2009013332A (es) | 2007-06-08 | 2010-01-25 | Mannkind Corp | Inhibidores de ire-1 alfa. |
FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
CN103119030A (zh) | 2010-07-30 | 2013-05-22 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
CN103228634A (zh) | 2010-09-24 | 2013-07-31 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
EP2926808A1 (en) | 2012-11-28 | 2015-10-07 | Administración General De La Communidad Autónoma De Euskadi | Use of metalloprotease inhibitors for the treatment of polycystic liver diseases |
AR107592A1 (es) | 2016-02-12 | 2018-05-16 | Astellas Pharma Inc | Derivados de tetrahidroisoquinolina |
CN110769866B (zh) * | 2017-06-13 | 2022-07-29 | 爱惜康有限责任公司 | 具有可控愈合的外科缝合器 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
WO1995029901A1 (en) * | 1994-04-28 | 1995-11-09 | Uniroyal Chemical Company, Inc. | Fungicidal azole derivatives |
EE9800172A (et) * | 1995-12-06 | 1998-12-15 | Astra Pharmaceuticals Limited | Ühendid |
AU725847B2 (en) | 1996-04-19 | 2000-10-19 | Merck Sharp & Dohme B.V. | Substituted benzylamines and their use for the treatment of depression |
ZA974032B (en) * | 1996-05-15 | 1998-02-19 | Bayer Ag | Substituted oxobutyric acids as matrix metalloproteinases inhibitors. |
US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
MXPA03009361A (es) * | 2001-04-13 | 2004-01-29 | Boehringer Ingelheim Pharma | Compuestos de urea utilies como agentes anti-inflamatorios. |
AU2003261319A1 (en) * | 2002-08-01 | 2004-02-23 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
ATE455096T1 (de) * | 2002-11-19 | 2010-01-15 | Galderma Res & Dev | Biaromatische verbindungen die ppar-gamma rezeptoren aktivieren und deren anwendungen in kosmetischen oder pharmazeutischen zusammensetzungen |
GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
EP1856063B1 (en) | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
ES2397284T3 (es) | 2006-08-22 | 2013-03-06 | Ranbaxy Laboratories Limited | Proceso para preparar inhibidores de la metaloproteinasa de la matriz y auxiliares quirales para los mismos |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es active Active
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 EP EP10176905A patent/EP2295408A1/en not_active Withdrawn
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de active Active
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Application Discontinuation
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es active Active
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko active Search and Examination
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en active Application Filing
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 EP EP08163972A patent/EP2042488B1/en active Active
- 2004-09-10 EP EP04765231A patent/EP1663970B1/en active Active
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de active Active
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Application Discontinuation
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
- 2006-11-15 HK HK06112572.5A patent/HK1092141A1/xx not_active IP Right Cessation
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
- 2008-12-19 HR HR20080668T patent/HRP20080668T3/xx unknown
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109400T1 (el) | Αναστολεις μεταλλοπρωτεϊνασης μητρας | |
BR0201697A (pt) | Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
ATE362910T1 (de) | Matrix metalloprotease inhibitoren | |
BR0306150A (pt) | Composto, uso de um composto, e, composição farmacêutica | |
MA27664A1 (fr) | Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
BRPI0417157A (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
BRPI0409049A (pt) | métodos de preparação de um composto, composição e composição cristalina | |
BR0100234A (pt) | Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
DE3883140D1 (de) | Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen. | |
MA29258B1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
PT77231A (en) | Process for the preparation of 2-nitro-1,1-ethenediamines having a hypotensive effect and their use for the preparation of pharmaceutical compositions with a hypotensive effect | |
EA200400848A1 (ru) | Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов | |
IL64081A (en) | N-alkoxycarbonyl-n'-substituted alkyl-n"-phenyl guanidines,process for their preparation and pharmaceutical compositions containing them | |
ATE250586T1 (de) | Imidazoline derivate,ihre herstellung und pharmazeutische zusammensetzungen die sie enthalten | |
ATE38987T1 (de) | Neue 2h-1-benzopyran-2-on-derivate, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten. | |
EA200000530A1 (ru) | НОВЫЕ 19-НОРСТЕРОИДЫ, ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 11β, СПОСОБ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
EA199901034A3 (ru) | Новые соединения 1,2-дитиолана, способ их получения и содержащие их фармацевтические составы | |
ATE239021T1 (de) | Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
BR0201312A (pt) | Compostos de pirimidin-4-ona, processo para sua preparação e composições farmacêuticas contendo os referidos | |
IT1213440B (it) | 2-ditioalchil-diidropiridine, un metodo per la loro preparazione e composizioni farmaceutiche chele contengono. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: GLAXO GROUP LIMITED (GB) |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |